A Phase 2 interventional study of Caplyta in Borderline Personality Disorder
Completed Phase 2 NCT05356013
Study Description
Evaluating the Safety and Effectiveness of Caplyta in Adults with Borderline Personality Disorder
Study Details
- Registry ID:
- NCT05356013
- Conditions:
- Borderline Personality Disorder
- Phase:
- Phase 2
- Target Enrollment:
- 60 participants
- Start Date:
- Age Range:
- 18–65 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
University of Chicago Medical Center
Chicago, Illinois, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.